Wolcott-Rallison Syndrome Due to a Novel Mutation (R491X) in EIF2AK3 Gene

Ercan Mıhçı1, Doğa Türkkahraman2, Sian Ellard3, Sema Akçurin4, İffet Bircan4

1 Akdeniz University School of Medicine, Department of Pediatrics, Division of Clinical Genetics, Antalya, Turkey
2 Antalya Education and Research Hospital, Department of Pediatric Endocrinology, Antalya, Turkey
3 Institute of Biomedical Science, Peninsula Medical School, University of Exeter, UK
4 Akdeniz University School of Medicine, Department of Pediatric Endocrinology, Antalya, Turkey

Introduction

Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disorder characterized by early-onset diabetes mellitus, skeletal dysplasia (especially multiple epiphyseal dysplasia), osteoporosis and growth retardation (1). Other occasional findings of WRS include central hypothyroidism, hepatic dysfunction, renal insufficiency, central nervous system abnormalities, cardiorespiratory defects, and hypothalamic-pituitary dysfunction (2,3,4,5,6,7). To date, less than 100 cases have been described (8). Mutations in the eukaryotic translation initiation factor 2α kinase (EIF2AK3) gene are responsible for this disorder (9). The EIF2AK3 gene regulates protein synthesis by phosphorylating the α-subunit of the eukaryotic initiation factor-2 (eIF2) in the endoplasmic reticulum and is specifically required in the insulin-secreting β-cells during fetal life and early neonatal period (10). Here, we report a novel nonsense mutation (R491X) in the EIF2AK3 gene in a patient with WRS.

Case Report

The male proband is an infant of Turkish ancestry who was born at 39 weeks gestation by caesarean section with a birth weight of 2300g (<3rd percentile, small for gestational age). His parents were second-degree cousins. Family history was unremarkable. At 2 months of age, the patient had been diagnosed to have neonatal diabetes. Diabetes-associated auto-antibodies were negative. He was discharged with a regimen of NPH and regular insulin injections twice a day.
At age 5.5 years, the patient was still on insulin therapy (0.9 U/kg/day). His HbA1c level was 7.7%. Mental-motor development was normal. His height percentile was below 3rd percentile (height SD score: -2.6) and his growth velocity was low (3.6 cm/year). Thyroid function tests were normal, and anti-gliadin IgA was negative for celiac disease. Bone age was retarded by 1.5 years. He had proportionate short stature, and had no sign of skeletal abnormalities.

At age 7 years, the patient was admitted to our hospital with a right-sided femur fracture following a simple trauma. X-ray films showed findings consistent with skeletal dysplasia. Additionally, he had a protuberant abdomen, lumbar lordosis and extension limitation in all joints (Figure 1). Height was severely retarded (102.6 cm, height SD score: -3.6). Growth velocity was 2 cm per year despite his better metabolic control. X-rays revealed beaking of both thoracic and lumbar vertebrae, spina bifida at L5 vertebrae and generalized epiphyseal-metaphyseal dysplasia (Figure 2). Dual-energy X-ray absorptiometry (DEXA) showed osteopenia according to height-age T2-L4 Z-score: -1.6), and abdominal ultrasonography revealed hypoplasia of the pancreas (severely atrophic). Cerebellar atrophy was detected on cranial magnetic resonance imaging.

These findings led us to re-evaluate the diagnosis of this patient. WRS was considered as the most plausible diagnosis because of coexistence of neonatal diabetes and skeletal abnormalities. At this time, the patient was found to have elevated liver enzyme values. However, these values decreased and returned to normal within a week and were linked to an episode of viral infection. Genomic DNA was extracted from peripheral leukocytes using standard procedures. The coding exons and the intron-exon boundaries of the EIF2AK3 gene were PCR-amplified; primers and conditions are available upon request. Sequence-specific primers for each amplicon were tagged with 5' M13 tails to allow sequencing to be performed with a "universal" M13 primer. Single-strand sequencing was performed using standard methods on an ABI 3730 (Applied Biosystems, Warrington, UK). Sequences were compared to the published template (accession number AF110146.1) using Mutation Surveyor v3.24 (SoftGenetics, PA, USA). Any changes in the sequence were checked against published polymorphisms and mutations and for conservation across species. Sequence variants were tested for their presence in family members whenever a DNA sample was available.

![Figure 1. Photograph of the patient demonstrating posture](image1)

![Figure 2. X-ray films demonstrating beaking of both thoracic and lumbar vertebrae, spina bifida at L5 vertebrae, generalized epiphyseal-metaphyseal dysplasia and osteopenia of the skeletal system](image2)

![Figure 3. Identification of the mutation in the EIF2AK3 gene. Sequences show normal DNA, heterozygous parents, and the findings in the patient](image3)
Sequencing analysis has shown that the patient is homozygous for a novel nonsense mutation, R491X (c.1471C>T; p.Arg491X), in exon 9 of the EIF2AK3 gene. Both his mother and father were heterozygous carriers for this mutation (Figure 3).

**Discussion**

Permanent neonatal diabetes mellitus (PNDM) is a very rare clinical condition defined as diabetes diagnosed within the first 6 months of life that does not remit. The estimated incidence of PNDM is 1 in 260,000 and it is most commonly caused by the mutations in the KCNJ11, ABCC8 and INS genes (11,12,13,14). The mutations in the gene encoding EIF2AK3 are responsible for WRS. Our patient was found to be homozygous for a novel nonsense mutation (R491X) in exon 9 of the EIF2AK3 gene. His mother and father, who were second cousins, were confirmed as heterozygous carriers. A recent study has shown that WRS is the most common cause of PNDM in consanguineous pedigrees (8). In addition to testing patients with a definite clinical diagnosis, these authors recommend that EIF2AK3 mutations should be sought in patients with isolated neonatal diabetes diagnosed after 3 weeks of age from known consanguineous families, isolated populations, or countries where inbreeding is common.

In the literature, the major skeletal abnormalities of WRS are listed as osteoporosis, osteopenia, thoracoolumbar kyphosis and bowing of the femora (6). In our patient, osteopenia, beaked thoracic and lumbar vertebrae, a spina bifida at L5 vertebrae and generalized epiphyseal-metaphyseal dysplasia were all present.

Various central nervous system anomalies including cerebellar cortical dysplasia, cerebral atrophy and pachygyria have been described in patients with WRS (6,15,16). Our patient was also found to have cerebellar hypoplasia, which is one of the very rare central nervous system abnormalities of WRS. Severe pancreatic hypoplasia with prominent islets of Langerhans, an important finding of WRS, was present in our patient as well. Notably, in our patient, even though we regulated his blood glucose levels with intensive insulin therapy, and excluded other possible pathologies, growth velocity remained very low. Low growth velocity in such patients might be an initial finding for suspecting WRS in patients presenting with subtle skeletal abnormalities.

In conclusion, the findings in this patient indicate that WRS can present initially as neonatal diabetes mellitus, obscuring the other findings of this syndrome. On the other hand, especially in consanguineous families, even when there is no evidence of skeletal abnormalities, the diagnosis of WRS should be kept in mind in infants/children with growth retardation.

**References**

1. Wolcott CD, Rallison ML. Infancy-onset diabetes mellitus and multiple epiphyseal dysplasia. J Pediatr 1972;80:292-297.
2. Abdelrahman S, Bin-Abbas B, Al-Ashwal A. Wolcott-Rallison syndrome in a Saudi infant. Curr Pediatr Res 2000;1:51-52.
3. Bin-Abbas B, Shabib S, Hainu B, Al-Ashwal A. Wolcott-Rallison syndrome. Clinical, radiological and histological finding in a Saudi child. Ann Saudi Med 2001;2:73-74.
4. Bin-Abbas B, Al-Mulhim A, Al-Ashwal A. Wolcott-Rallison syndrome in two siblings with isolated central hypothyroidism. Ann J Med Genet 2002;111:187-190.
5. Brickwood S, Bonthron DT, Al-Gazali LJ, Piper K, Hearnt T, Wilson DI, Hanley NA. Wolcott-Rallison syndrome: pathogenic insights into neonatal diabetes from new mutation and expression studies of EIF2AK3. J Med Genet 2003;40:685-689.
6. Iyer S, Korada M, Rainbow L, Kirk J, Brown RM, Shaw N, Barrett TG. Wolcott-Rallison syndrome: a clinical and genetic study of three children, novel mutation in EIF2AK3 and review of the literature. Acta Paediatr 2004;93:1195-1201.
7. Engelmann G, Meyburg J, Shahbek N, Al-Ali M, Hairetis MH, Baker AJ, Rodenburg RJT, Wening D, Flechtenmacher C, Ellard S, Smetintk JA, Hoffmann GF, Buchanan CR. Recurrent acute liver failure and mitochondriopathy in a case of Wolcott-Rallison syndrome. J Inherit Metab Dis 2008;31:540-546.
8. Rubio-Cabezas O, Patch AM, Minton JA, Flanagan SE, Edghill EL, Hussain K, Balafrej A, Deeb A, Buchanan CR, Jefferson IG, Maturi A; Neonatal Diabetes International Collaborative Group, Hattersley AT, Ellard S. Wolcott-Rallison syndrome is the most common genetic cause of permanent neonatal diabetes in consanguineous families. J Clin Endocrinol Metab 2009;94:4162-4170.
9. Delépine M, Nicolino M, Barrett, Golamaully M, Lathrop GM, Julien C, EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000;25:406-409.
10. Biason-Lauber A, Lang-Murtano M, Vaccaro T, Schoenle EJ. Loss of kinase activity in a patient with Wolcott-Rallison syndrome caused by a novel mutation in the EIF2AK3 gene. Diabetes 2002;51:2301-2305.
11. Slingerland AS, Shields BM, Flanagan SE, Bruining GJ, Noordam K, Gach A, Mynarski W, Malecki MT, Hattersley AT, Ellard S. Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia 2009;52:1683-1685.
12. Gloyn AL, Cummings EA, Edghill EL, Harries LW, Scott R, Costa T, Temple IK, Hattersley AT, Ellard S. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab 2004;8:3932-3935.
13. Babenko AP, Polak M, Cävé H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P. Activating mutations in the ABC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-466.
14. Stoy J, Edghill EL, Flanagan SE, Ye H, Paz VP, Pluzhnikov A, Belov JE, Hayes MG, Cox NJ, Lipkind GM, Lipton RB, Greeley SA, Patch AM, Ellard S, Steiner DF, Hattersley AT, Philipson LH, Bell GI; Neonatal Diabetes International Collaborative Group. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA 2007;104:15040-15044.
15. Thornton CM, Carson DJ, Stewart FJ. Autopsy findings in the Wolcott-Rallison syndrome. Pediatr Pathol Lab Med 1997;17:487-496.
16. de Wit MC, de Coo IF, Julien C, Delépine M, Lequin MH, van de Laar I, Sibbels BJ, Bruining GJ, Mancini GM. Microcephaly and simplified gyral pattern of the brain associated with early onset insulin-dependent diabetes mellitus. Neurogenetics 2006;7:259-263.